Consensus Savara Inc.

Stocks

SVRA

US8051111016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 23:31:45 29/10/2026 +04			5-day change	1st Jan Change
4.975 ^USD	-0.90%		+9.47%	-17.58%

10-21	Savara Inc. Presents New Data Showing Molgramostim Inhalation Solution Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis Patients with Mild Diffusion Impairment	CI
10-13	Savara Inc. Announces New Analysis From The IMPALA Clinical Trial And Encore Presentation Of Long-Term Data On Molgramostim In Autoimmune Pulmonary Alveolar Proteinosis At CHEST 2026	CI

Evolution of the Average Target: Savara Inc.

Evolution of the Target Price: Savara Inc.

Changes in Analyst Recommendations: Savara Inc.

6b5f3c19d5.yXK2Bxkq2VbJsDgaJy59zlHlQYwD-29yTtQ861rNarY.hCjBa3tdtSeawEl_HnoWtxWDJPhMuQ1HKp9wjDuVAsWfHfM2SWSRObHbdQ~bec9f427355ac7b24cbe1019011d6a92

Analysts' recommendations: Savara Inc.

10-07	JPMorgan Initiates Savara at Overweight With $12 Price Target	MT
04-24	Oppenheimer Adjusts Price Target on Savara to $11 From $9, Maintains Outperform Rating	MT
11-14	Oppenheimer Adjusts Price Target on Savara to $9 From $8, Maintains Outperform Rating	MT
08/09/25	Oppenheimer Adjusts Savara Price Target to $8 From $6, Maintains Outperform Rating	MT
15/08/25	Savara Shares Rise After Upgrade From HC Wainwright	MT
15/08/25	HC Wainwright Upgrades Savara to Buy From Neutral, $5 Price Target	MT
15/08/25	Oppenheimer Adjusts Price Target on Savara to $6 From $5, Maintains Outperform Rating	MT
02/06/25	Oppenheimer Adjusts Price Target on Savara to $5 From $15, Maintains Outperform Rating	MT
29/05/25	HC Wainwright Downgrades Savara to Neutral From Buy, Adjusts Price Target to $2 From $6	MT
20/12/24	Wells Fargo Initiates Coverage on Savara With Overweight Rating, $8 Price Target	MT
13/11/24	Savara Shares Fall After Evercore ISI Downgrade	MT
13/11/24	Evercore ISI Downgrades Savara to In Line From Outperform, Adjusts Price Target to $5 From $7	MT
27/06/24	JMP Securities Adjusts Price Target on Savara to $10 From $8, Maintains Market Outperform Rating	MT
27/06/24	Oppenheimer Adjusts Price Target on Savara to $15 From $11, Maintains Outperform Rating	MT
27/06/24	Guggenheim Adjusts Price Target on Savara to $10 From $8, Maintains Buy Rating	MT
27/06/24	HC Wainwright Raises Savara Price Target to $10 From $6, Maintains Buy Rating	MT
21/05/24	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating	MT
04/03/24	Piper Sandler Adjusts Price Target on Savara to $16 From $7, Maintains Overweight Rating	MT
15/02/24	JMP Securities Starts Savara With Market Outperform Rating, $8 Price Target	MT
07/11/23	Guggenheim Starts Savara With Buy Rating, $7 Price Target	MT
14/08/23	HC Wainwright Adjusts Price Target on Savara to $6 From $3, Keeps Buy Rating	MT
03/04/23	Jefferies Downgrades Savara to Hold From Buy With $2 Price Target	MT
16/03/21	Savara : Piper Sandler Starts Savara at Overweight With $7 Price Target	MT
15/03/21	Savara : Oppenheimer Initiates Savara at Outperform With $4 Price Target	MT
15/12/20	Savara : HC Wainwright Adjusts Savara's Price Target to $3 From $6, Keeps at Buy	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SAVARA INC.					+120.23%
	WUXI APPTEC CO., LTD.					+41.72%
	ARGENX SE					+26.36%
	LONZA GROUP AG					+10.61%
	IQVIA HOLDINGS INC.					+10.61%
	BEONE MEDICINES AG					+16.9%
	REVOLUTION MEDICINES, INC.					+37.16%
	CELLTRION, INC.					+42.61%
	GENMAB A/S					-17.48%
	WUXI BIOLOGICS (CAYMAN) INC.					+30.19%
	Average					+31.89%
	Weighted average by Cap.					+23.02%